Experience

SinoVeda Canada Inc.

• Senior Scientist Molecular Pharmacology at Sinoveda Canada Inc.

  • Jul 2019 - Present



NanoSpeed Diagnostics Inc.

• Medical Equipment Manufacturing
• 1 - 100 Employee

• Scientist

  • Mar 2019 - Jun 2019

  R&D: Development of diagnostic/screening test kit platforms based on Lateral Flow Immuno-Assay (LIFA) and development of Point-of-Care Testing (POCT) platforms. R&D: Development of diagnostic/screening test kit platforms based on Lateral Flow Immuno-Assay (LIFA) and development of Point-of-Care Testing (POCT) platforms.



48Hour Discovery INC.

• Scientist- Molecular Biology

  • Dec 2018 - Jan 2019



University of Calgary

• Canada
• Higher Education
• 700 & Above Employee

• Research Assistant

  • Aug 2017 - Nov 2018

  Proteins Expression and Purification (mid- to large-scale in Bioreactor Wave System using mammalian cells including CHO and HEK 293 cell lines).Industrial collaboration (Novartis) for development of nanoparticles used as therapy for autoimmune diseases. Proteins Expression and Purification (mid- to large-scale in Bioreactor Wave System using mammalian cells including CHO and HEK 293 cell lines).Industrial collaboration (Novartis) for development of nanoparticles used as therapy for autoimmune diseases.



Libin Cardiovascular Institute of Alberta, Cumming School of medicine at University of Calgary

• Postdoctoral Researcher

  • Jun 2014 - Mar 2016

  Investigated the role of the small Heat Shock Protein 27 (HSP27) on Pro-Atherogenic lipoproteins metabolism and the molecular mechanisms behind the Atheroprotective effect of this protein Investigated the role of the small Heat Shock Protein 27 (HSP27) on Pro-Atherogenic lipoproteins metabolism and the molecular mechanisms behind the Atheroprotective effect of this protein



Group on the Molecular and Cell Biology of Lipids/Alberta Diabetes Institute, University of Alberta

• Postdoctoral Researcher

  • Jun 2012 - May 2014

  The goal of the project was to target Phosphatidylethanolamine N-methyltransferase (PEMT) as therapy for Type 2 Diabetes and Obesity. We sought to investigate whether the lack of hepatic phosphatidylethanolamine N-methyl transferase (PEMT) is solely responsible for the protection of Pemt Knockout (Pemt-/-) mice against obesity and insulin resistance The goal of the project was to target Phosphatidylethanolamine N-methyltransferase (PEMT) as therapy for Type 2 Diabetes and Obesity. We sought to investigate whether the lack of hepatic phosphatidylethanolamine N-methyl transferase (PEMT) is solely responsible for the protection of Pemt Knockout (Pemt-/-) mice against obesity and insulin resistance



Laboratory of Enzymology at Interfaces and Physiology of Lipolysis (EIPL), UMR7282, CNRS

• Postdoctoral Researcher

  • Jul 2010 - Apr 2012

  Lipid Formulation Classification System (LFCS) consortium project: Evaluate the extent of digestion of lipid-based formulations by gastric lipaseCollaboration with pharmaceutical industries (Sanofi- Aventis, Gattefossé, Capsugel…), and Monash (Australia) and Copenhagen (Danmark) universitiesMy research project within the LFCS consortium lies in developing standard methods to evaluate in vitro, the fate of poorly water soluble oral drugs formulated with lipid excipients, under conditions mimicking the digestion in the gastrointestinal tract DAGOIL Project: Developing enzymatic assays for production of 1, 2(2, 3)-diacylglycerols from refined rapeseed oil (Industrial collaboration)